Clinical trialsCompany release
Pyxis Oncology reports 39% confirmed response rate for micvotabart pelidotin in head and neck cancer
🇺🇸 Pyxis Oncology, Inc. (PYXS) · Thu 19 Nov 2026
Updated Phase 1 data for the antibody-drug conjugate in second-line-plus recurrent or metastatic HNSCC show a median response duration of 9.2 months, with a Phase 3 planned for mid-2027.
Pyxis Oncology has released updated Phase 1 monotherapy results for its antibody-drug conjugate micvotabart pelidotin (MICVO) in patients with second-line-plus recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The data cutoff was 14 October 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Pyxis Oncology, Inc. ↗
Article written by VigiEye from the official source (Pyxis Oncology, Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
PMV Pharma reports 48% response rate for rezatapopt in platinum-resistant ovarian cancer
🇺🇸 PMV Pharmaceuticals, Inc. (PMVP) · Fri 20 Nov 2026
J&J's Tremfya beats placebo in Phase 4 STAR axial psoriatic arthritis study at Week 24
Johnson & Johnson EMEA · Fri 20 Nov 2026
Immutep reports 81% 12-month disease-free survival in neoadjuvant soft tissue sarcoma trial
IMMUTEP Ltd (IMMP) · Fri 20 Nov 2026
BfArM lists ArcRoyal field safety notice for procedure trays containing BD Connecta Stopcock
🇩🇪 BfArM field safety notices · Thu 19 Nov 2026
FDA allows Alpha Tau to double REGAIN glioblastoma trial to 20 patients
Alpha Tau Medical Ltd. (DRTS) · Thu 19 Nov 2026
Health Canada posts Type II recall of Philips Bridge Prep Kit over guidewire resistance
🇨🇦 Health Canada · Thu 19 Nov 2026